Archive: Company News
Company News: Provecs Medical Announces Publication of Scientific Review of Gene Therapy in Oncology
— Peer-reviewed paper in Human Gene Therapy provides comprehensive overview of using gene therapy to address multiple targets
Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the publication of a review highlighting the use of gene therapy approaches in immuno-oncology to address multiple targets with a single drug. The paper entitled “Immuno-Oncology – the Translational Runway for Gene Therapy” will appear in the December issue of Human Gene Therapy, a peer-reviewed publication covering all aspects of human gene therapy.
Company News: Agena Bioscience´s Liquid Biopsy Technology Awarded Horizon 2020 Grant by European Union
Agena Bioscience, a global provider of molecular genetic solutions, today announced it has been selected to participate as an innovative technology provider in the ‘Liquid biopsies and IMAging for improved cancer care’ (LIMA) project.
The LIMA project has been awarded a EUR 6.3 million Horizon 2020 European Union research grant to develop an integrated approach for personalized cancer treatment. The objective of the four-year project is to develop and validate liquid biopsy technologies in the clinical workflow and to provide more precise, dynamic tumor characterization during diagnosis and treatment.
Company News: BioNTech Honored as WuXi AppTec Biotech Company of the Year at Scrip Awards 2017
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has received the WuXi AppTec Biotech Company of the Year Award at the 2017 Scrip Awards ceremony in London.
Company News: Molecular Health and U.S. Food and Drug Administration (FDA) Extend Software Collaboration to Drug Safety Prediction
Molecular Health, Inc (MH), a company marketing computational biomedicine tools to support healthcare decisions with clinical and molecular data, and the FDA’s Center for Drug Evaluation and Research (CDER) have extended for an additional 5 years, their research collaboration to jointly address one of the biggest challenges in drug development: the prediction of drug safety.